Holen Sie sich die Stockscreener-App
7.45
4.73%
-0.37
Handel nachbörslich:
7.45
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
Phathom Pharmaceuticals CFO Molly Henderson sells $10,328 in stock - Investing.com India
Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells 1,291 Shares of Stock - MarketBeat
Phathom Pharmaceuticals COO sells shares for $8,944 - Investing.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 2%What's Next? - MarketBeat
Phathom Pharmaceuticals Inc (PHAT) Recovers 28.94% From Low: Are We There Yet? - Stocks Register
FDA Tracker: FDA Hands Out Atopic Dermatitis Approvals to Galderma, Organon - BioSpace
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up After Insider Buying Activity - Defense World
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Frank Karbe buys $99,083 in Phathom Pharmaceuticals stock By Investing.com - Investing.com Australia
Frank Karbe buys $99,083 in Phathom Pharmaceuticals stock - Investing.com India
Phathom Pharmaceuticals director Asit Parikh buys $81,248 in stock By Investing.com - Investing.com South Africa
How To Trade (PHAT) - Stock Traders Daily
Insider Buying: Asit Parikh Acquires 10,000 Shares of Phathom Ph - GuruFocus.com
Frank Karbe Increases Stake in Phathom Pharmaceuticals Inc (PHAT) - GuruFocus.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up on Insider Buying Activity - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director Acquires $99,125.00 in Stock - MarketBeat
Phathom Pharmaceuticals director Asit Parikh buys $81,248 in stock - Investing.com
Insider Sellers Might Regret Selling Phathom Pharmaceuticals Shares at a Lower Price Than Current Market Value - Simply Wall St
Charles Schwab Investment Management Inc. Purchases 6,990 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals Submits Citizen Petition to FDA for Correction of Orange Book Listings for VOQUEZNA Tablets - Defense World
Phathom Pharma shares stay Buy rated on extended vonoprazan exclusivity to 2032 - Investing.com Canada
Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)? - MSN
Phathom Pharmaceuticals (NASDAQ:PHAT) Receives "Buy" Rating from HC Wainwright - MarketBeat
Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable (NASDAQ:PHAT) - Seeking Alpha
Phathom Pharmaceuticals seeks FDA clarity on drug exclusivity - Investing.com
Phathom Pharmaceuticals seeks FDA clarity on drug exclusivity By Investing.com - Investing.com UK
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets - The Manila Times
Phathom Pharmaceuticals Submits Citizen Petition to FDA - GlobeNewswire
Fmr LLC Boosts Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround - MSN
Point72 Asset Management L.P. Takes Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Wasatch Advisors LP Buys Shares of 246,942 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 3.5%Should You Sell? - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Short Interest Update - MarketBeat
Eagle Asset Management Inc. Increases Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
(PHAT) Technical Pivots with Risk Controls - Stock Traders Daily
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap DownTime to Sell? - MarketBeat
Jennison Associates LLC Has $106.06 Million Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know - MSN
Phathom Pharmaceuticals - The Healthcare Technology Report.
(PHAT) Proactive Strategies - Stock Traders Daily
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2024 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Up 115.60% This Year: What Is Going To Happen Next - Stocks Register
Phathom Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Business Updates - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.9%Here's What Happened - MarketBeat
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlig - GuruFocus.com
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):